|
Benfotiamine
European Supplement Protects
Against Diabetic Complications
By Dale Kiefer
When treating diabetes, today's doctors focus on
establishing blood glucose control, but often overlook the
need to protect against common diabetic complications such
as blindness, stroke, endothelial dysfunction, and loss of
limb.1
Fortunately, benfotiamine, a little-known fat-soluble
form of vitamin B1, has been shown to help prevent the
development and progression of many diabetic complications. As a result, benfotiamine has become a critical nutrient for
those seeking to ward off the potentially lethal impact of
sustained high blood sugar levels.
Used for decades in Europe as a prescription medication,
benfotiamine ameliorates the progression of diabetic nerve,
kidney, and retinal damage, and relieves the painful
symptoms of diabetic neuropathy.2-8
Diabetic neuropathy makes it difficult for nerves to carry
messages to the brain and also impairs the function of the
microvasculature (tiny blood vessels) in the extremities. The result of this pathological blood-vessel damage is
numbness and painful tingling in the feet (and hands) that
can eventually result in amputation of the lower
extremities.
Benfotiamine acts through a novel mechanism, blocking the
biochemical pathways by which high blood sugar damages cells
throughout the body.8
Now available as a low-cost dietary supplement, benfotiamine
can help diabetes sufferers protect their nerves, kidneys,
eyes, blood vessels, and heart. Benfotiamine’s multifaceted
effects in preventing dangerous diabetic complications make
it an essential supplement for people with elevated blood
sugar levels.
Benfotiamine Differs from Conventional Diabetes Drugs
Diabetes drugs are among the most widely prescribed
pharmaceuticals on the market today. Current medications for
type II diabetes seek to reduce the dangerous buildup of
excess sugar (glucose) in the bloodstream by either
increasing insulin production or enhancing its
effectiveness.
Benfotiamine is one of the most effective yet overlooked
treatments for preventing the debilitating complications of
diabetes. Benfotiamine is a chemical sibling of the
essential nutrient thiamine (vitamin B1). Thiamine helps to
convert fats and carbohydrates into glucose, a form of fuel
for the body. As such, thiamine is essential for the proper
regulation of glucose metabolism.9
However, while thiamine is soluble only in water,
benfotiamine is fat soluble, a characteristic that allows it
to enter cells far more readily than thiamine and thus help
to prevent diabetes-related dysfunction within the cells. This enhanced bioavailability makes benfotiamine
particularly effective in treating hyperglycemia-related
damage to tissues and organs.10-12
Benfotiamine's Biochemical Response to High Blood Sugar
Diabetes treatments that seek to increase insulin output
or improve the cells' response to insulin do not provide
adequate protection against the many complications of the
disease. While diabetes medications help tackle the problem
of inordinately high levels of plasma glucose, only
benfotiamine reduces elevated levels of intracellular
glucose and alters the body’s biochemical response to the
toxic breakdown products of excess sugar. Benfotiamine
stimulates the production of transketolase, a naturally
beneficial enzyme that efficiently converts these
potentially toxic glucose breakdown products into harmless
compounds that can be safely eliminated by the body.
Numerous studies have shown that benfotiamine inhibits
three major pathways that lead to the formation of toxic
substances such as advanced glycation end products (AGEs).5,8,13
AGEs have been implicated in the development and
progression of numerous disorders in diabetics. These
include:
-
Cardiovascular disease14
-
Diabetic neuropathy (nerve disorders)15,16
-
Retinopathy (affecting vision)15,16
-
Peripheral vascular disease (affecting blood vessels
of the extremities)15,16
-
Nephropathy (kidney disease).15,16
Interestingly, AGE-associated damage to the
cardiovascular system is also seen in aging adults without
diabetes. In fact, aging itself is considered a major risk
factor for the development of cardiac dysfunction, due to
the accumulation of AGEs over time, even in non-diabetics. AGEs are believed to act through several mechanisms to
promote vascular damage, scar tissue formation, and
inflammation.14
Unfortunately, this process is simply accelerated in
diabetics,17 which
suggests that even non-diabetics can benefit from
benfotiamine’s ability to inhibit AGE formation.
Years of use as a prescription drug in Europe have shown
that benfotiamine is safe and well tolerated.3,6,7,18,19
Now that it is available in the United States as a low-cost
dietary supplement, researchers are turning their attention
to benfotiamine and uncovering evidence that it helps to
offset the dangers of numerous complications of diabetes and
high blood sugar.
Benfotiamine Protects Delicate Nerve and Brain Tissue
The nervous system can suffer in numerous ways from the
damaging effects of high blood sugar. Comprising brain,
spinal cord, and peripheral nerves, the nervous system
controls the functions of muscles and organs, coordinates
thoughts and actions, and conveys sensory information.
Neuropathy, or nerve disease, is one of the most
prevalent and painful complications of diabetes.
Characteristics of diabetic neuropathy include:
-
Damage to the peripheral nerves of the extremities
-
Pain that may be unresponsive to conventional pain
relievers
-
Numbness and altered sensation affecting the limbs
-
Nerves of the extremities may malfunction
simultaneously, causing polyneuropathy.
Clinical trials demonstrate that benfotiamine effectively
relieves diabetic polyneuropathy. A recent random,
double-blind study in Germany found that diabetes patients
with polyneuropathy who supplemented with 100 mg of
benfotiamine four times daily for three weeks demonstrated
statistically significant improvement in nerve function
scores. A decrease in pain was the most pronounced effect
noted. The study authors said their findings support the
results of two earlier randomized, controlled trials, which
also found evidence of benfotiamine’s beneficial effects in
patients with diabetic neuropathy.3
Diabetes has been associated with increased oxidative
stress, a contributor to many age-related disease processes. Delicate brain tissue is especially susceptible to the
damaging effects of oxidative stress. As a result, diabetes
is increasingly associated with cognitive decline, including
dementia and Alzheimer’s. (See "The Deadly Connection
Between Diabetes and Alzheimer’s," Life Extension, December
2006.)
A newly released study indicates that benfotiamine may
protect the brain against oxidative stress associated with
diabetes. Investigators experimentally induced diabetes in a
group of test subjects. Following two weeks of induced high
blood sugar levels, the subjects received two weeks of
benfotiamine supplementation. Benfotiamine alleviated the
oxidative stress in the brain that typically occurs with
diabetes, leading the research team to conclude that
benfotiamine may avert diabetes-induced cerebral oxidative
stress through a novel mechanism.20
This important finding means that benfotiamine offers
critical protection for the delicate nervous system by
shielding the peripheral nerves and brain from damage caused
by diabetes.
Benfotiamine Optimizes Endothelial and Vascular Function
In clinical studies from around the world, benfotiamine
has repeatedly demonstrated remarkable effects in
normalizing endothelial function.
Endothelial cells line the interior of blood vessels. These specialized cells are commonly damaged by high blood
sugar and diabetes. When blood vessels are unable to relax
and dilate in response to increased blood flow demands, the
result is the dangerous condition known as endothelial
dysfunction. Endothelial dysfunction is believed to
contribute to the initiation of atherosclerosis and to
underlie much of the damage associated with the
complications of diabetes, particularly peripheral vascular
disease.
Peripheral vascular disease occurs when blood flow
through arteries in the arms and legs is impaired. Dangers
of peripheral vascular disease include:
-
Impaired blood flow to the extremities that can
cause cramping pain with walking (intermittent
claudication)
-
Cuts or abrasions on the feet that fail to heal
-
Ulcers and gangrene of the feet and legs that can
necessitate amputation.21
German scientists recently investigated benfotiamine’s
effectiveness in supporting healthy endothelial function and
peripheral blood flow. In the study, diabetic patients
consumed a meal containing large amounts of advanced
glycation end products (AGEs) derived from foods cooked at
high temperatures. AGEs are known to contribute to
endothelial dysfunction. The subjects ate the AGE-rich meal
both before and after three days of treatment with
benfotiamine. Indicators of endothelial function, oxidative
stress, and AGEs were measured after an overnight fast on
the test days, and at two, four, and six hours after the
test meals.22
The AGE-rich meal alone produced several harmful changes,
including:
-
Significantly decreased blood flow to the
extremities;
-
Increased blood markers of endothelial dysfunction;
-
Elevation in oxidative stress; and
-
Higher levels of AGEs.22
The detrimental changes caused by the AGE-rich meal alone
were completely prevented by supplementation with
benfotiamine. Benfotiamine promoted numerous improvements,
including:
-
Enhanced blood flow in the extremities;
-
Improved endothelial function;
-
Diminished oxidative stress; and
-
Normalization of AGE levels.22
This important German study demonstrates that AGEs
directly contribute to vastly diminished vascular function
in diabetics, and that the use of benfotiamine prevents
AGE-induced endothelial dysfunction, impaired blood flow,
and increased oxidative stress.22
Two recent studies from Italy validate benfotiamine's
ability to support healthy endothelial function, even in the
presence of high blood glucose levels. Independent Italian
research teams showed that, in addition to preserving mature
endothelial cells lining blood vessels, benfotiamine also
protects endothelial progenitor cells, or cells that develop
into endothelial cells. These progenitor cells are crucial
to the repair and maintenance of healthy endothelial tissue.23,24
While hyperglycemia, or high blood sugar, interferes with
the normal development of progenitor cells, the Italian
scientists noted that normal development of these cells can
be restored by the administration of benfotiamine.23
Similarly, benfotiamine inhibited human epithelial
progenitor cell death, which is caused by high glucose
levels.24
Benfotiamine’s ability to support the health of
endothelial cells may have important implications in helping
people to avoid peripheral vascular disease. Scientists now
believe that the endothelial dysfunction that occurs with
diabetes can easily lead to diabetic peripheral vascular
disease.16
Japanese researchers found that peripheral arterial
disease affecting the legs' blood vessels commonly occurs
together with endothelial dysfunction. As a result, the legs
do not receive the critical supply of blood and oxygen they
need to stay healthy and functional.25
Moreover, diabetic patients with peripheral arterial disease
have fewer circulating endothelial progenitor cells, which
are necessary to keep blood vessels functioning optimally so
they can deliver blood to the limbs.26
In a model of peripheral vascular disease, benfotiamine
improved endothelial function, which restored circulation to
the legs and increased blood and oxygen supply to the
tissues. This is especially important in keeping the limbs
healthy and avoiding amputation, an all-too-common
consequence of vascular dysfunciton. Additionally,
benfotiamine reduced the diabetes-induced deficit in
endothelial progenitor cells, which led to improved healing
responses in the legs of diabetic subjects.24
Benfotiamine Reduces Heart Disease Risk
Individuals with diabetes suffer from a greatly increased
risk of heart disease. Benfotiamine may play an important
role in strategies to protect heart health in people with
high blood sugar.
A recent study conducted by researchers at the University
of Wyoming gauged benfotiamine's ability to prevent heart
disease in an experimental model of human type II diabetes. One group was rendered diabetic, while a second control
group remained normal. Both groups received benfotiamine
therapy for two weeks. Scientists then examined heart cells
from both groups, assessing their ability to contract and
various biochemical parameters.27
As expected, diabetes was associated with increased
oxidative stress, which interfered with the healthy function
of heart muscle. Benfotiamine treatment alleviated many of
the heart cell changes caused by diabetes, decreasing
oxidative stress and restoring heart cell function. The
researchers concluded that benfotiamine may guard heart
muscle cells against the dysfunction associated with
diabetes.27
Supplementing with benfotiamine may thus be crucial in
protecting the heart against the adverse effects of
diabetes.
Benfotiamine Promotes Kidney Health
Kidney disease, or nephropathy, is one of the most
dreaded complications of diabetes. When kidney function
deteriorates in people with diabetes, the kidneys may no
longer be able to perform their crucial task of filtering
urine. As a result, diabetics with advanced nephropathy must
resort to kidney dialysis or a kidney transplant. Kidney
disease also increases the risk of cardiovascular disease
and overall mortality.
In a 24-week study, scientists examined the effects of
benfotiamine and thiamine on subjects with diabetes. Both
forms of vitamin B1 produced beneficial changes in markers
of kidney function and health, including:
-
A 70-80 percent inhibition in the development of
microalbuminuria, protein in the urine that serves as an
early sign of kidney dysfunction.
-
A normalization of enzyme activity associated with
protection against kidney disease.
-
A 50 percent reduction of AGE levels in the kidneys.
-
A reduction in oxidative stress associated with
diabetes (produced by benfotiamine but not by thiamine).5,10
The scientists noted that while both benfotiamine and
thiamine helped prevent the kidney complications associated
with diabetes, benfotiamine appears to be a superior choice
due to its greater bioavailability in the body.5,10
This research indicates benfotiamine and thiamine may help
people with diabetes safeguard the health of their kidneys
and protect against the devastating consequences of
nephropathy.
Benfotiamine Helps to Avert Vision Loss
While diabetes threatens whole-body health, the eyes are
particularly vulnerable to damage. Damage to small blood
vessels caused by diabetes can result in retinopathy (a
disease of the eye's retina, which collects visual
information) and even blindness.
Scientists in Germany discovered that administration of
benfotiamine helped to prevent retinopathy in test subjects
with diabetes. Study subjects who received benfotiamine for
36 weeks demonstrated completely normalized levels of
damaging AGEs in the retina, leading the research team to
conclude that benfotiamine may help prevent or delay the
onset and progression of diabetic retinopathy.8
Benfotiamine appears to provide essential protection to
the eyes, helping prevent vision-robbing diabetic
retinopathy.
Conclusion
For decades, benfotiamine has been safely used as a
prescription drug in Europe, where this natural vitamin B1
derivative has demonstrated efficacy in preventing many
serious complications of prolonged hyperglycemia.
Consumers in America can now readily access benfotiamine
as a low-cost dietary supplement. Laboratory investigations
and controlled studies have confirmed that benfotiamine
alleviates and may even reverse diabetic neuropathy, kidney
disease, cardiac impairment, endothelial dysfunction,
peripheral vascular disease, and diabetic retinopathy. With
its proven ability to confer broad-spectrum support for the
blood vessels, nerves, kidneys, eyes, and heart,
benfotiamine should be considered a first-line defense
against the debilitating consequences of diabetes and high
blood sugar.
References
1. Diglas
J, Willinger C, Neu U, Irsigler K. Morbidity and mortality
in type 1 and type 2 diabetes mellitus after the diagnosis
of diabetic retinopathy. Dtsch Med Wochenschr. 1992 Nov
6;117(45):1703-8.
2. Stracke H, Hammes HP, Werkmann D, et
al. Efficacy of benfotiamine versus thiamine on function and
glycation products of peripheral nerves in diabetic rats. Exp Clin Endocrinol Diabetes. 2001;109(6):330-6.
3. Haupt E, Ledermann H, Kopcke W. Benfotiamine in the
treatment of diabetic polyneuropathy—a three-week
randomized, controlled pilot study (BEDIP study). Int J Clin
Pharmacol Ther. 2005 Feb;43(2):71-7.
4. Sanchez-Ramirez GM, Caram-Salas NL, Rocha-Gonzalez HI,
et al. Benfotiamine relieves inflammatory and neuropathic
pain in rats. Eur J Pharmacol. 2006 Jan 13;530(1-2):48-53.
5. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S,
Thornalley PJ. Prevention of incipient diabetic nephropathy
by high-dose thiamine and benfotiamine. Diabetes. 2003
Aug;52(8):2110-20.
6. Woelk H, Lehrl S, Bitsch R, Kopcke W. Benfotiamine in
treatment of alcoholic polyneuropathy: an 8-week randomized
controlled study (BAP I Study). Alcohol Alcohol. 1998
Nov;33(6):631-8.
7. Winkler G, Pal B, Nagybeganyi E, et al. Effectiveness
of different benfotiamine dosage regimens in the treatment
of painful diabetic neuropathy. Arzneimittelforschung. 1999
Mar;49(3):220-4.
8. Hammes HP, Du X, Edelstein D, et al. Benfotiamine
blocks three major pathways of hyperglycemic damage and
prevents experimental diabetic retinopathy. Nat Med. 2003
Mar;9(3):294-9.
9. Arora S, Lidor A, Abularrage CJ, et al. Thiamine
(vitamin B(1)) improves endothelium-dependent vasodilatation
in the presence of hyperglycemia. Ann Vasc Surg. 2006 May
31.
10. [No authors listed]. Benfotiamine Monograph. Altern
Med Rev. 2006;11(3):238-42.
11. Pomero F, Molinar MA, La SM, et al. Benfotiamine is
similar to thiamine in correcting endothelial cell defects
induced by high glucose. Acta Diabetol. 2001;38(3):135-8.
12. Bitsch R, Wolf M, Moller J, Heuzeroth L, Gruneklee D. Bioavailability assessment of the lipophilic benfotiamine as
compared to a water-soluble thiamin derivative. Ann Nutr
Metab. 1991;35(5):292-6.
13. Beltramo E, Berrone E, Buttiglieri S, Porta M. Thiamine and benfotiamine prevent increased apoptosis in
endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev. 2004 Jul;20(4):330-6.
14. Thomas MC, Baynes JW, Thorpe SR, Cooper ME. The role
of AGEs and AGE inhibitors in diabetic cardiovascular
disease. Curr Drug Targets. 2005 Jun;6(4):453-74.
15. Cameron NE, Gibson TM, Nangle MR, Cotter MA.
Inhibitors of advanced glycation end product formation and
neurovascular dysfunction in experimental diabetes. Ann NY
Acad Sci. 2005 Jun;1043:784-92.
16. Sheehan P. Peripheral arterial disease in people with
diabetes: consensus statement recommends screening. Clinical
Diabetes. 2004:22:179-80.
17. Li SY, Du M, Dolence EK, et al. Aging induces cardiac
diastolic dysfunction, oxidative stress, accumulation of
advanced glycation endproducts and protein modification. Aging Cell. 2005 Apr;4(2):57-64.
18. Sadekov RA, Danilov AB, Vein AM. Diabetic
polyneuropathy treatment by milgamma-100 preparation. Zh
Nevrol Psikhiatr Im SS Korsakova. 1998;98(9):30-2.
19. Kolomoiskaia MB, Degonskii AI, Grishina RA. The
myocardial contractile function and central hemodynamics of
patients with insulin-dependent diabetes mellitus during
treatment. Probl Endokrinol (Mosk). 1989 Jul;35(4):12-5.
20. Wu S, Ren J. Benfotiamine alleviates diabetes-induced
cerebral oxidative damage independent of advanced glycation
end-product, tissue factor and TNF-alpha. Neurosci Lett.
2006 Feb 13;394(2):158-62.
21. Available at:
http://www.diabetesselfmanagement.com/article.cfm?aid=558. Accessed October 23, 2006.
22. Stirban A, Negrean M, Stratmann B, et al. Benfotiamine prevents macro- and microvascular endothelial
dysfunction and oxidative stress following a meal rich in
advanced glycation end products in individuals with type 2
diabetes. Diabetes Care. 2006 Sep;29(9):2064-71.
23. Marchetti V, Menghini R, Rizza S, et al. Benfotiamine
counteracts glucose toxicity effects on endothelial
progenitor cell differentiation via Akt/FoxO signaling. Diabetes. 2006 Aug;55(8):2231-7.
24. Gadau S, Emanueli C, Van LS, et al. Benfotiamine
accelerates the healing of ischaemic diabetic limbs in mice
through protein kinase B/Akt-mediated potentiation of
angiogenesis and inhibition of apoptosis. Diabetologia. 2006
Feb;49(2):405-20.
25. Sanada H, Higashi Y, Goto C, Chayama K, Yoshizumi M,
Sueda T. Vascular function in patients with lower extremity
peripheral arterial disease: a comparison of functions in
upper and lower extremities. Atherosclerosis. 2005
Jan;178(1):179-85.
26. Fadini GP, Miorin M, Facco M, et al. Circulating
endothelial progenitor cells are reduced in peripheral
vascular complications of type 2 diabetes mellitus. J Am
Coll Cardiol. 2005 May 3;45(9):1449-57.
27. Ceylan-Isik AF, Wu S, Li Q, Li SY, Ren J. High-dose
benfotiamine rescues cardiomyocyte contractile dysfunction
in streptozotocin-induced diabetes mellitus. J Appl Physiol.
2006 Jan;100(1):150-6.
28. Lonsdale D. A review of the biochemistry, metabolism
and clinical benefits of thiamin(e) and its derivatives. Evid Based Complement Alternat Med. 2006 Mar;3(1):49-59. |